Celiac disease (CD) is a common autoimmune disease caused by exposure to the protein gliadin in wheat, and related prolamins in barley and rye. The prevalence of the disease in the US is 1:133. The aim of this study was to identify non-human leukocyte antigen (HLA) loci that predispose to CD. A genome-wide search of 405 microsatellite markers was performed on DNA samples from 160 families with a minimum of two cases of CD. Multipoint, parametric and non-parametric linkage (NPL) analyses were performed. Locations on chromosomes 1q, 3q, 6p, 6q, 7q, 9q and 10q showed linkage statistics (NPL scores or heterogeneity logarithm of the odds (HLOD) scores) of approximately 2.0 or larger. The greatest evidence for linkage outside of chromosome 6 was on 7q and 9q. An NPL score of 2.60 occurred at position 151.0 on 7q and a HLOD score of 2.47 occurred at position 144.8 on 9q under a recessive model. As expected, there was highly significant linkage to the HLA region on 6p, with NPL and HLOD scores exceeding 5.50. In conclusion, this genome-wide linkage analysis represents one of the largest such studies of CD. The most promising region is a putative locus on 7q, a region reported independently in previous genome-wide searches.
Introduction
Celiac disease (CD, gluten-sensitive enteropathy, celiac sprue) is a common disease, with a recent estimate that the disease frequency is 1:133 in the general population in the US, 1 similar to European estimates. CD is a familial, autoimmune disease with significant morbidity if untreated. It is caused by sensitivity to the dietary protein gliadin, which is present in wheat, and to the related prolamins, secalin in rye and hordein in barley. The term gluten-sensitive enteropathy refers to the histologic abnormality of the small intestine, which ranges from minimal lymphocytic infiltration of the intestinal epithelium to severe atrophy of the villi. 2 CD is one of the most significant causes of chronic malabsorption in children. Symptoms include growth failure, abdominal pain and diarrhea. Occult disease is frequently present with minimal symptoms or signs. Complications of CD include lymphoma, osteoporosis, anemia and seizures. No pharmacological treatment is available. Although treatment with a gluten-free diet will improve symptoms, recurrence of symptoms and complications may occur after minor dietary indiscretions.
CD may serve as a model for autoimmune diseases because, in contrast to most other human leukocyte antigen (HLA)-associated autoimmune diseases, the trigger (gliadin) and the highly specific autoimmune response (autoantibodies to tissue transglutaminase (tTG)) are known.
Families with multiple cases of CD are common, and estimates for the risk to siblings have ranged from less than 5% to greater than 20%, with most estimates between 10-12%. [2] [3] [4] [5] CD has a strong genetic association with the HLA class II DQ2 genotype composed of the DQA1*05 and DQB1*02 alleles. This genotype is found in greater than 90% of celiac cases of northern European descent and in approximately 12-26% of controls. [6] [7] [8] An additional 5% of celiacs carry the DQ8 genotype composed of the DQA1*03 and DQB1*0302 alleles. 9 However, the HLA association alone is insufficient to explain the hereditary nature of the disease, and is estimated to explain less than half the sibling risk, [10] [11] [12] [13] indicating the presence of one or more additional susceptibility loci.
CD is a complex trait with several genes involved in disease susceptibility. There have been multiple genomewide studies to identify loci for CD. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] All studies have identified significant linkage evidence to the HLA region, but there have been few significant linkages outside the HLA region and little to no confirmation of suggestive linkages. For complex diseases, difficulty in finding significant evidence for linkage and non-replication of linkage results are common, and may be due to the low power of studies to detect genes of relatively small effect and/or to a high degree of genetic heterogeneity among families. Larger data sets with more power are needed to map complex disease susceptibility genes, including CD. Altmuller et al. 25 reviewed 101gen-ome-wide linkage studies for complex diseases, and found that the only factors independently associated with study success were a large sample size and the study of one ethnic group (compared to multiple ethnic groups).
We have carried out a genome-wide linkage analysis of 160 North American Caucasian families with 2 to 13 cases of CD. Given the complex nature of the disease and the lack of a clear model of inheritance, both parametric (model-based) and non-parametric (model-free) linkage analyses were performed. This study represents the largest set of North American families for linkage analysis of CD to date.
Results
The genome-wide analysis identified six regions across the genome that showed lower than average information content provided by the microsatellite marker coverage as well as a linkage statistic exceeding 1.5. Additional markers were genotyped on chromosomes 1, 3, 7, 10, 12 and 14. These six chromosomes were reanalyzed for linkage with the additional markers and the results presented below included additional markers. Figure 1 shows the results of the multipoint linkage analysis for all chromosomes except 6 (shown on Figure 2 because of different scaling Genome-wide linkage analysis celiac disease CP Garner et al Figure 2 shows the results of the multipoint linkage analysis of chromosome 6. As expected, highly significant NPL scores and HLOD scores, including both the dominant and recessive models, were observed across the HLA region. The recessive HLOD score and NPL score were of similar size (5.84 and 5.53, respectively) with the peaks in the respective multipoint curves occurring at positions 34.0 and 42.0. The maximum multipoint HLOD score under the dominant model was 4.46 and occurred at position 49.2. The multipoint linkage analysis of chromosome 6 suggests three peaks across the chromosome. The tri-modal pattern is observed for all three multipoint curves. The first peak is most pronounced and occurs over the HLA region between the 20 and 60 cM locations. A second peak, that is likely an artifact of the strong linkage to HLA occurs between the 80 and 110 cM locations and is most pronounced under the recessive model. The third peak is clearly distinct from the other two, occurs at the 155.0 cM location. A HLOD score of 2.44 was shown under the recessive model at position 155.0 of chromosome 6, with the NPL score in the same location being 1.41; no evidence for linkage was observed in this location under the dominant model.
Discussion
The HLA region accounts for a large proportion of the risk for CD and showed the strongest evidence for linkage in this and all previous linkage analyses. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Based on previous heritability studies, segregation Because of the close association of CD and the HLA DQ genotypes, it is difficult to identify if there are other genes in the region accounting for susceptibility to CD risk. There have been several studies attempting to investigate other genes. The association of two major histocompatibility class I-related (MIC) genes located within the HLA I class I region and CD was studied in a small sample of 133 Spanish CD cases, of whom 79 had classic symptoms and 54 had atypical symptoms (non-classic or no symptoms), and 116 unaffected controls.
27,28 MICA5.1 was significantly associated with the atypical CD, as was the MICB0106 allele, which is in strong linkage disequilibrium with MICA5.1. The association of two microsatellites, tumor necrosis factor (TNF)a and b, near the TNF genes, in the class III region of the MHC and CD was investigated in 49 cases sand 59 controls, and TNFa2 was associated with CD, independent of DQ2. 29 Of the 160 families included in this analysis, 44 had been studied in a previous parametric linkage analysis of 62 families. 15 In the previous analysis, there were 128 CD cases in the 62 families, whereas in this study, there were 562 CD cases in 160 families. The families that we enrolled since the previous study are larger and with more affected individuals. Previously, we had identified evidence for linkage at 18q32 in a set of non-HLA families (defined as those in which all cases did not have the high risk HLA genotype), yet saw no evidence of any linkage in this analysis. Similar to the previous linkage analysis, we had nominal evidence for linkage at 10p14-p11 (NPL ¼ 2.1 and previous multipoint HLOD ¼ 2.1) and at 12p13-p12 (NPL ¼ 1.7 and previous two-point HLOD ¼ 1.4). Other loci with evidence for linkage were not in common. Consistent with the results reported here, Rioux 21 provided evidence for linkage to chromosome 10p (NPL ¼ 1.93). There have also been independent reports of linkage to the 7q31-q35 region; Zhong et al. 19 reported a LOD score of 2.99 (P ¼ 0.0018) and King et al. 16 reported a LOD score of 0.9 at D7s507 (at approximately 7q34). These additional reports support further investigation of these regions, particularly 7q31-35 where we obtained a maximum NPL of 2.60.
There have been many genome-wide celiac linkage studies for which there has been suggestive or significant evidence for linkage to 2q23-33, 3p, 4p14-15, 5p, 5q31,  5qter, 6p21-23, 7q31, 10p12, 10q23, 11p11, 11qter, 15q11-13, 15q26, 16q23, 17q12, 18q23, 19p13.3, 22cen. 14-24 Many of these studies included a small number of families and most of these regions of interest have not been replicated, suggesting genetic heterogeneity and/or false positives and providing a story that is consistent with other complex diseases. Even within Finland, three studies did not identify regions in common. 14, 21, 22 The regions, other than HLA, 7q31-31 and 10p13-p11 that were identified more than once with at least nominal evidence for linkage were 5q31, 18, 19 30 However, in studies of a Swedish/Norwegian cohort and a British cohort, there was no association of MYO9B and CD. 31, 32 The genome-wide linkage analysis reported here represents one of the largest such studies of CD reported to date, and in an ethnically homogeneous sample. It is clear that after accounting for HLA, there is genetic heterogeneity for CD. There appear to be different genes in different families that predispose to disease and that several genes will need to be found. More genotyping and analysis needs to be performed across the six non-HLA regions showing NPL or HLOD scores of approximately 2.0 or greater to increase the information content and decrease the size of the regions. A promising candidate locus on 7q is supported from previous independent studies. Although the evidence for linkage to 7q is not considered significant after accounting for the large number of statistical tests in the genome-wide analysis, it remains the top priority for further genetic mapping.
Methods

Study population
Families with a minimum of two cases of CD or dermatitis herpetiformis were ascertained through gastroenterologists, gluten intolerance support groups, selfreferral and advertising at local and national CD support meetings throughout North America. There was no selection of cases based on sex, race or age. All families meeting the inclusion criteria were Caucasian. The families are from throughout North America, and none of the families appear to be related. The research study, begun at the University of Utah and continued at the University of California Irvine, was approved by the University of Utah and University of California Irvine Institutional Review Boards. Participants ranged in age from 1 to 95 years. Blood samples were collected from affected individuals and their first-degree relatives. For more distantly related CD cases, we also collected blood from individuals that connected the cases. For example, for two affected first cousins, we would collect samples from the first cousins, their parents, and their grandparents, if possible. In the 160 families studied, 1121 DNA samples were sent for genotyping, including 544 cases with CD, 18 cases with dermatitis herpetiformis, and 559 samples from their unaffected relatives. The number of celiac cases per family ranged from 2 to 13. Fourteen of the 160 families had one case with dermatitis herpetaformis and two families had two cases of dermatitis herpetiformis.
Diagnostic criteria
An individual was considered as having CD if the diagnosis had been made by one or more of the following: small intestinal biopsy satisfying the European Society of Pediatric Gastroenterology and Nutrition (ESPGHAN) criteria, 33 biopsy-proven dermatitis herpetiformis and/or positive immunoglobulin (Ig)A endomysial antibody (EMA) and IgA tTG antibody serologies. Medical records were reviewed to confirm previous biopsy-proven CD or dermatitis herpetiformis. Testing for IgA EMA, IgA tTG antibodies and quantitative serum IgA levels was performed on sera from all participants. IgA EMA was measured by indirect immunofluorescence using monkey esophagus substrate and fluorescein isothiocyanate-conjugated antibodies to human IgA. 34, 35 Screening was performed with three twofold dilutions of patients' sera, at dilutions of 1:5, 1:10 and 1:20. Limiting dilutions on positive sera were carried out with successive twofold dilutions until endomysial staining was no longer present for the end point titer. IgA tTG-Ab was measured using standard enzyme-linked immunoabsorbant assay technology with human recombinant tTG as a substrate (INOVA Diagnostics, San Diego, CA, USA). IgA EMA end point titers greater than or equal to 1:10 and IgA tTG antibody levels greater than 20 U were considered positive. Total serum IgA levels were measured using standard radial-immunodiffusion methods (Beckman Coulter, Brea, CA, USA).
The high sensitivity and specificity of serum IgA EMA and tTG antibody tests for CD of greater than 95%, makes them useful markers for diagnosing CD. [36] [37] [38] Patients with Crohn's disease, ulcerative colitis, primary biliary cirrhosis and autoimmune hepatitis may have increased IgA tTG antibodies, 39 ,40 therefore, we required both increased IgA EMA and IgA tTG antibody levels for a diagnosis of CD. Moreover, patients with mild or intermediate mucosal changes, as may be observed in early CD, may have negative antibody tests. [41] [42] [43] We recognize that we may miss up to 10% of asymptomatic CD cases. However, the near perfect specificity of the IgA EMA test indicates that we will not create false positive diagnoses. In cases in which both increased IgA EMA and tTG antibodies are detected, we inform participants of their results and recommend that decisions for small intestinal biopsy for a definitive diagnosis be made with their physicians.
Genotyping of short-tandem repeat markers DNA was extracted from lymphocytes. DNA concentrations were quantified and adjusted to 10 ng/ml. Ten micrograms DNA from 1121 samples was sent to the Center for Inherited Disease Research (CIDR) (www.cidr.jhmi.edu) for genotyping. They performed genotyping using a 10 cM density microsatellite marker genome scan of 405 short-tandem repeat (STR) markers. After obtaining the genotyping data, we analyzed the genotype data from the 160 families for inconsistencies with Mendelian inheritance using the program Pedcheck. 44 For each Mendelian inconsistency, genotypes of all individuals that were potential sources of the error within a pedigree were set to missing values for the marker.
Twenty-seven additional microsatellite markers were genotyped to increase the identity by descent information content across six of the seven regions meeting a minimal threshold of evidence for linkage. One of the seven regions was HLA on chromosome 6 and no additional genotyping was carried out in this region because it is a known celiac susceptibility locus. STR markers were ordered from the Applied Biosystems (Foster City, CA, USA) marker set. Polymerase chain reaction (PCR) was performed under standard conditions. After PCR, approximately five to seven STRs of different sizes and fluorescence tags were pooled and genotyped on an ABI 3100 Sequencer. Allele calls were assigned using Genemapper Version 3.5.
Statistical analysis
Multipoint, parametric (model-based) and non-parametric (model-free) linkage analysis of CD was carried out using Genehunter version 2.1 for the autosomal genome and version 1.3 for chromosome X. Genehunter version 1.3 was the last version to incorporate the xgh function for linkage analysis of chromosome X. Maximum likelihood estimates of the marker allele frequencies were computed from the pedigree data and used in the linkage analysis. NPL scores were computed to assess the statistical evidence for linkage in the nonparametric analysis and HLOD scores were computed for the parametric analysis. HLOD scores were computed under a dominant and a recessive model. The dominant model was defined by a disease mutation having a frequency of 0.0001, and penetrance values of 0.001, 0.50 and 0.50, for the wild-type homozygote, the heterozygote and the disease allele homozygote genotypes, respectively. The recessive model was defined by a disease mutation having a frequency of 0.01, and penetrance values of 0.001, 0.001 and 0.50 for the wildtype homozygote, heterozygote and disease allele homozygote genotypes, respectively. All of the affected pedigree members could be included in the analysis with the program's maximum bits value set at 21; two to four unaffected pedigree members had to be excluded from three of the largest pedigrees to achieve a practical computation time. The Marshfield sex-averaged linkage maps 45 were used to determine the marker order and inter-marker distances for the multipoint analysis.
